دورية أكاديمية
أعرض في EDS

Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine.

التفاصيل البيبلوغرافية
العنوان: Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine.
المؤلفون: Hilberink JR; Department of Hematology, University Medical Center Groningen, Groningen, the Netherlands., van Zeventer IA; Department of Hematology, University Medical Center Groningen, Groningen, the Netherlands., Chitu DA; Department of Hematology, HOVON Data Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Pabst T; Department of Oncology, University Hospital, Inselspital, and University of Bern, Bern, Switzerland., Klein SK; Department of Hematology, University Medical Center Groningen, Groningen, the Netherlands.; Department of Internal Medicine, Meander Hospital Amersfoort, Amersfoort, the Netherlands., Stussi G; Department of Hematology, Oncology Institute of Southern Switzerland, Ospedale Regionale, Bellinzona, Switzerland., Griskevicius L; Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos, Vilnius University, Vilnius, Lithuania., Valk PJM; Department of Hematology, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Cloos J; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands., van de Loosdrecht AA; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands., Breems D; Department of Hematology, ZNA Stuivenberg/Middelheim, Antwerp, Belgium., van Lammeren-Venema D; Department of Hematology, Hagaziekenhuis, Den Haag, the Netherlands., Boersma R; Department of Hematology, Amphia Hospital, Breda, the Netherlands., Jongen-Lavrencic M; Department of Hematology, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Fehr M; Department of Medical oncology and Hematology, Kantonsspital St. Gallen, St. Gallen, Switzerland., Hoogendoorn M; Department of Hematology, Medical Center Leeuwarden, Leeuwarden, the Netherlands., Manz MG; Department of Medical Oncology and Hematology, Universitätsspital Zurich, Zurich, Switzerland., Söhne M; Department of Hematology, Antonius Hospital, Nieuwegein, the Netherlands., van Marwijk Kooy R; Department of Hematology, Isala Hospital, Zwolle, the Netherlands., Deeren D; Department of Hematology, AZ Delta Roeselare, Roeselare, Belgium., van der Poel MWM; Department of Internal Medicine, Division of Hematology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands., Legdeur MC; Department of Hematology, Medical Spectrum Twente, Enschede, the Netherlands., Tick L; Department of hematology, Maxima Medical Center, Veldhoven, the Netherlands., Chalandon Y; Division of hematology, University Hospital Genève and Faculty of Medicine, University of Genève, Genève, Switzerland., Ammatuna E; Department of Hematology, University Medical Center Groningen, Groningen, the Netherlands., Blum S; Service and Central Laboratory of Hematology, Department of Oncology and Department of Laboratory Medicine and Pathology, Lausanne University Hospital (CHUV), Lausanne, Switzerland., Löwenberg B; Department of Hematology, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Ossenkoppele GJ; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands., Huls G; Department of Hematology, University Medical Center Groningen, Groningen, the Netherlands. g.huls@umcg.nl.
مؤلفون مشاركون: Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Swiss Group for Clinical Cancer Research (SAKK)
المصدر: Blood cancer journal [Blood Cancer J] 2023 Jun 19; Vol. 13 (1), pp. 93. Date of Electronic Publication: 2023 Jun 19.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE
أسماء مطبوعة: Original Publication: New York, NY : Nature Pub. Group
مواضيع طبية MeSH: Myelodysplastic Syndromes*/genetics , Leukemia, Myeloid, Acute*/genetics, Humans ; Male ; Female ; Aged ; Decitabine/therapeutic use ; Mutation ; Treatment Outcome
مستخلص: Treatment choice according to the individual conditions remains challenging, particularly in older patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). The impact of performance status, comorbidities, and physical functioning on survival is not well defined for patients treated with hypomethylating agents. Here we describe the impact of performance status (14% ECOG performance status 2), comorbidity (40% HCT-comorbidity index ≥ 2), and physical functioning (41% short physical performance battery < 9 and 17% ADL index < 6) on overall survival (OS) in 115 older patients (age ≥ 66 years) treated on a clinical trial with a 10-day decitabine schedule. None of the patient-related variables showed a significant association with OS. Multivariable analysis revealed that age > 76 years was significantly associated with reduced OS (HR 1.58; p = 0.043) and female sex was associated with superior OS (HR 0.62; p = 0.06). We further compared the genetic profiles of these subgroups. This revealed comparable mutational profiles in patients younger and older than 76 years, but, interestingly, revealed significantly more prevalent mutated ASXL1, STAG2, and U2AF1 in male compared to female patients. In this cohort of older patients treated with decitabine age and sex, but not comorbidities, physical functioning or cytogenetic risk were associated with overall survival.
(© 2023. The Author(s).)
References: J Clin Oncol. 2014 Aug 20;32(24):2541-52. (PMID: 25071138)
Lancet Haematol. 2023 Feb;10(2):e117-e128. (PMID: 36436542)
J Clin Oncol. 2011 Jun 1;29(16):2240-6. (PMID: 21537048)
Leuk Lymphoma. 2017 Jun;58(6):1325-1331. (PMID: 27774847)
Leukemia. 2017 Feb;31(2):318-324. (PMID: 27795561)
Leukemia. 2020 Jul;34(7):1751-1759. (PMID: 32020044)
Blood. 2015 Jan 29;125(5):767-74. (PMID: 25515963)
Blood. 2001 Sep 1;98(5):1312-20. (PMID: 11520776)
Haematologica. 2012 Dec;97(12):1916-24. (PMID: 22773600)
Cancer. 2006 Mar 1;106(5):1090-8. (PMID: 16435386)
Leuk Lymphoma. 2013 Sep;54(9):2003-7. (PMID: 23270581)
Blood. 2016 Aug 4;128(5):686-98. (PMID: 27288520)
Blood. 2013 May 23;121(21):4287-94. (PMID: 23550038)
Blood. 2017 Jan 26;129(4):424-447. (PMID: 27895058)
Haematologica. 2011 Mar;96(3):441-9. (PMID: 21134982)
Leuk Res. 2012 Apr;36(4):479-82. (PMID: 22192632)
Blood Adv. 2022 Jun 28;6(12):3812-3820. (PMID: 35420672)
N Engl J Med. 2020 Aug 13;383(7):617-629. (PMID: 32786187)
Blood. 2022 Sep 15;140(11):1200-1228. (PMID: 35767897)
Am J Clin Oncol. 1982 Dec;5(6):649-55. (PMID: 7165009)
Cancer. 2007 Apr 1;109(7):1376-83. (PMID: 17326052)
N Engl J Med. 2009 Sep 24;361(13):1235-48. (PMID: 19776405)
Br J Haematol. 2009 Jun;145(5):598-605. (PMID: 19344426)
Blood. 2009 Apr 30;113(18):4179-87. (PMID: 19008455)
Haematologica. 2013 Feb;98(2):208-16. (PMID: 22875615)
Blood. 2006 May 1;107(9):3481-5. (PMID: 16455952)
BMC Med. 2016 Dec 22;14(1):215. (PMID: 28003033)
Blood. 2009 Oct 1;114(14):2869-77. (PMID: 19667402)
Blood. 2015 Jul 16;126(3):283-4. (PMID: 26185114)
Leukemia. 2021 Mar;35(3):867-870. (PMID: 32576964)
Geriatr Gerontol Int. 2013 Apr;13(2):421-8. (PMID: 22882512)
Blood. 2005 Oct 15;106(8):2912-9. (PMID: 15994282)
Blood Adv. 2020 Sep 22;4(18):4267-4277. (PMID: 32915972)
Blood. 2015 Jul 16;126(3):291-9. (PMID: 25987659)
Hemasphere. 2023 Jan 24;7(2):e832. (PMID: 36713353)
Blood. 2010 Nov 25;116(22):4422-9. (PMID: 20668231)
Gerontologist. 1970 Spring;10(1):20-30. (PMID: 5420677)
Leukemia. 2015 Mar;29(3):548-55. (PMID: 25092141)
Br J Haematol. 2007 Feb;136(4):624-7. (PMID: 17223919)
N Engl J Med. 2015 Sep 17;373(12):1136-52. (PMID: 26376137)
Blood. 2018 Nov 8;132(19):2100-2103. (PMID: 30242087)
J Clin Oncol. 2012 Jul 20;30(21):2670-7. (PMID: 22689805)
Leukemia. 2018 Jun;32(6):1338-1348. (PMID: 29563537)
Blood. 2022 Mar 17;139(11):1646-1658. (PMID: 35007323)
Am J Hematol. 2021 Mar 1;96(3):282-291. (PMID: 33264443)
فهرسة مساهمة: Investigator: DA Chitu; SK Klein; L Griskevicius; PJM Valk; J Cloos; AA van de Loosdrecht; D Breems; D van Lammeren-Venema; R Boersma; M Jongen-Lavrencic; M Söhne; R van Marwijk Kooy; D Deeren; MWM van der Poel; MC Legdeur; L Tick; E Ammatuna; B Löwenberg; GJ Ossenkoppele; G Huls; T Pabst; G Stussi; M Fehr; MG Manz; Y Chalandon; S Blum
المشرفين على المادة: 776B62CQ27 (Decitabine)
تواريخ الأحداث: Date Created: 20230619 Date Completed: 20230621 Latest Revision: 20230701
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC10279734
DOI: 10.1038/s41408-023-00850-6
PMID: 37336890
قاعدة البيانات: MEDLINE
الوصف
تدمد:2044-5385
DOI:10.1038/s41408-023-00850-6